{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:53Z","timestamp":1787026613534,"version":"build-2736575974"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Daily use of low concentrations of atropine is recommended for children undergoing myopia control therapy. While the benefits of controlling myopia progression have been confirmed, the potential unwanted side effects on the ocular surface, pupil size, and quality of vision following the administration of 0.01% atropine have not been investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This single-arm, self-control study aimed to investigate the short-term effects of 0.01% atropine topical eye drop (He Eye Hospital Co., Ltd., Shenyang, China) on pupil size and subjective quality of vision in participants with myopia. Each 3\u2009mL vial of eye drops contains atropine (0.01%), sodium chloride (0.9%), and benzalkonium chloride (0.005%) in an aqueous solution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-three adults (66 eyes) were recruited for the study. The mean age of the participants recruited for this study was 24.91\u2009\u00b1\u20093.36\u2009years. This study is registered with Clinical Trials.gov (NCT06071260). Assessments were performed at baseline and 10\u2009h, 14\u2009h, and 18\u2009h following the administration of 0.01% topical atropine drop (TAD). Mesopic pupil diameter (MPD), photopic pupil diameter (PPD), higher order aberration (HOA), non-invasive tear breakup time (NITBUT), tear meniscus height (TMH), tear film lipid layer (TFLL), and Redness score (RS). Subjective assessments included the quality of vision (QoV) and the ocular surface disease index (OSDI) questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Following the use of 0.01% atropine, PPD significantly increased at all the time points (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001); MPD increased significantly at 10\u2009h and 14\u2009h (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05, respectively). A decrease in TMH and an increase in the OSDI questionnaire scores were observed up to 10 and 14\u2009h, respectively, after using atropine (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Glare (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004 at 10\u2009h and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003 at 14\u2009h), blurred vision (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.0001 at 10\u2009h and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035 at 14\u2009h), and focusing difficulties (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.0001 at 10\u2009h and\n                      <jats:italic>p\u2009&amp;lt;<\/jats:italic>\n                      0.0001 at 14\u2009h) were significantly higher at both 10\u2009h and 14\u2009h after using atropine. No significant changes were observed in the HOA, NITBUT, and RS scores (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05) at all time points.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Decreased TMH, dry eye symptoms, and visual symptoms will likely persist overnight but often diminish within 18\u2009h after using 0.01% atropine eye drops.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2024.1436551","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T12:42:51Z","timestamp":1725540171000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Short-term effects of ophthalmic topical 0.01% atropine on the ocular surface, pupil size, and subsequent subjective quality of vision in young myopic Chinese adults"],"prefix":"10.3389","volume":"11","author":[{"given":"Mingze","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sile","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingru","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Eric","family":"Pazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/S00417-019-04555-0","article-title":"Stopping the rise of myopia in Asia","volume":"258","author":"Spillmann","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/iovs.62.5.3","article-title":"IMI risk factors for myopia","volume":"62","author":"Morgan","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/OPX.0000000000002022","article-title":"Comparison of three different devices for the evaluation of axial length, refractive error, and Keratometry","volume":"100","author":"Hessler","year":"2023","journal-title":"Optom Vis Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0002-9394(14)76891-6","article-title":"Prevalence of lattice degeneration and its relation to axial length in severe myopia","volume":"111","author":"Celorio","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"6612476","DOI":"10.1155\/2021\/6612476","article-title":"Comparing school-aged refraction measurements using the 2WIN-S portable refractor in relation to Cycloplegic retinoscopy: a cross-sectional study","volume":"2021","author":"Liu","year":"2021","journal-title":"J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"CD014758","DOI":"10.1002\/14651858.CD014758.pub2","article-title":"Interventions for myopia control in children: a living systematic review and network meta-analysis","volume":"2","author":"Lawrenson","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1136\/BJO-2022-322808","article-title":"Five-year results of atropine 0.01% efficacy in the myopia control in a European population","volume":"108","author":"Moriche-Carretero","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12886-020-01746-W","article-title":"Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1136\/bjo-2022-321272","article-title":"Effect of atropine, orthokeratology and combined treatments for myopia control: a 2-year stratified randomised clinical trial","volume":"107","author":"Xu","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e079833","DOI":"10.1136\/bmjopen-2023-079833","article-title":"Protocol for a parallel assignment prospective, randomised, double-blinded, placebo-controlled trial to evaluate the efficacy of 0.01% atropine for near work-induced transient myopia and myopic progression in China","volume":"13","author":"Qin","year":"2023","journal-title":"BMJ Open"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1475-1313.1987.tb01004.x","article-title":"A review of the uses and adverse effects of topical administration of atropine","volume":"7","author":"North","year":"1987","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1136\/bjophthalmol-2019-314819","article-title":"Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK) \u2013 study protocol","volume":"104","author":"Azuara-Blanco","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2 myopia control with atropine 0.01% Eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/jop.2017.0144","article-title":"A review of myopia control with atropine","volume":"34","author":"Tran","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1113\/jphysiol.1926.sp002315","article-title":"The antagonism of acetyl choline by atropine","volume":"61","author":"Clark","year":"1926","journal-title":"J Physiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/PHARMACEUTICS14050900","article-title":"The role of atropine in preventing myopia progression: an update","volume":"14","author":"Chierigo","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.4103\/IJO.IJO_165_18","article-title":"Allergic reactions to atropine eye drops for retardation of progressive myopia in children","volume":"66","author":"Kothari","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/eye.2016.78","article-title":"Effectiveness study of atropine for progressive myopia in Europeans","volume":"30","author":"Polling","year":"2016","journal-title":"Eye"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"646530","DOI":"10.3389\/fphar.2021.795205","article-title":"Case report: multiple seizures after a Diphenoxylate-atropine overdose in a small child","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1136\/bjophthalmol-2019-315440","article-title":"Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression","volume":"104","author":"Fu","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"624472","DOI":"10.3389\/fnins.2021.624472","article-title":"The effects of 0.01% atropine on adult Myopes\u2019 contrast sensitivity","volume":"15","author":"Cheng","year":"2021","journal-title":"Front Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"109331","DOI":"10.1016\/j.mehy.2019.109331","article-title":"Will the long-term use of atropine eye drops in children increase the risk of dry eye?","volume":"132","author":"Zhao","year":"2019","journal-title":"Med Hypotheses"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/BIOMEDICINES8040078","article-title":"Atropine differentially modulates ECM production by ocular fibroblasts, and its ocular surface toxicity is blunted by colostrum","volume":"8","author":"Cristaldi","year":"2020","journal-title":"Biomedicines"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/cxo.12109","article-title":"Evaluation of the auto-refraction function of the Nidek OPD-scan III","volume":"97","author":"Mcginnigle","year":"2014","journal-title":"Clin Exp Optom"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"E35198","DOI":"10.1097\/MD.0000000000035198","article-title":"The influence of pupil diameter upon and subjective quality of vision following implantable collamer lens (ICL V4c) implantation: an observational study","volume":"102","author":"Zhang","year":"2023","journal-title":"Medicine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clae.2012.04.002","article-title":"Clinical evaluation of the Oculus Keratograph","volume":"35","author":"Best","year":"2012","journal-title":"Cont Lens Anterior Eye"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/8013621","article-title":"Repeatability and reproducibility of noninvasive Keratograph 5M measurements in patients with dry eye disease","volume":"2016","author":"Tian","year":"2016","journal-title":"J Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1167\/iovs.10-5341","article-title":"The development of an instrument to measure quality of vision: the quality of vision (QoV) questionnaire","volume":"51","author":"McAlinden","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1089\/photob.2019.4788","article-title":"Subjective quality of vision in evaporative dry eye patients after intense pulsed light","volume":"38","author":"Fan","year":"2020","journal-title":"Photobiomodul Photomed Laser Surg"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"834","DOI":"10.18240\/ijo.2021.06.07","article-title":"Reliability of Chinese web-based ocular surface disease index (C-OSDI) questionnaire in dry eye patients: A randomized, crossover study","volume":"14","author":"Zhang","year":"2021","journal-title":"Int J Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1074272","DOI":"10.3389\/fpubh.2023.1074272","article-title":"Effect of atropine 0.01% on myopia control in children aged 6\u201313 years during the 2022 lockdown in Shanghai","volume":"11","author":"Yu","year":"2023","journal-title":"Front Public Health"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"756398","DOI":"10.3389\/FMED.2021.756398\/BIBTEX","article-title":"Varying dose of atropine in slowing myopia progression in children over different follow-up periods by Meta-analysis","volume":"8","author":"Gan","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1095495","DOI":"10.3389\/FPED.2023.1095495\/BIBTEX","article-title":"Effect of 0.02 and 0.01% atropine on ocular biometrics: a two-year clinical trial","volume":"11","author":"Wang","year":"2023","journal-title":"Front Pediatr"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1227787","DOI":"10.3389\/FPHAR.2023.1227787\/BIBTEX","article-title":"Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis","volume":"14","author":"Hou","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia a meta-analysis","volume":"135","author":"Gong","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05, 0.025, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/jcph.2320","article-title":"Incidence of adverse events induced by atropine in myopic children: a meta-analysis","volume":"63","author":"Sun","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/ame2.12218","article-title":"Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate","volume":"5","author":"S\u00e1nchez-R\u00edos","year":"2022","journal-title":"Animal Model Exp Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/tvst.13.4.22","article-title":"Differential impact of 0.01 and 0.05% atropine Eyedrops on ocular surface in Young adults. Transl Vis","volume":"13","author":"Luo","year":"2024","journal-title":"Sci Technol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"101409","DOI":"10.1016\/j.clae.2021.01.004","article-title":"Modifiable lifestyle risk factors for dry eye disease","volume":"44","author":"Wang","year":"2021","journal-title":"Cont Lens Anterior Eye"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia","volume":"46","author":"Upadhyay","year":"2020","journal-title":"Eye Contact Lens"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/08164622.2022.2033603","article-title":"Symptoms and ocular findings associated with administration of 0.01% atropine in young adults","volume":"106","author":"Cyphers","year":"2023","journal-title":"Clin Exp Optom"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1167\/iovs.16-20903","article-title":"The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells","volume":"58","author":"Datta","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/cxo.12967","article-title":"Which low-dose atropine for myopia control?","volume":"103","author":"Khanal","year":"2020","journal-title":"Clin Exp Optom"},{"key":"ref46","year":""}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1436551\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T12:42:54Z","timestamp":1725540174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1436551\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":46,"alternative-id":["10.3389\/fmed.2024.1436551"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1436551","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"article-number":"1436551"}}